[HTML][HTML] Focus: Genome editing: Gene therapy for color blindness

MM Hassall, AR Barnard… - The Yale journal of …, 2017 - ncbi.nlm.nih.gov
Achromatopsia is a rare congenital cause of vision loss due to isolated cone photoreceptor
dysfunction. The most common underlying genetic mutations are autosomal recessive …

AAV-mediated gene supplementation therapy in achromatopsia type 2: preclinical data on therapeutic time window and long-term effects

R Mühlfriedel, N Tanimoto, C Schön… - Frontiers in …, 2017 - frontiersin.org
Achromatopsia type 2 (ACHM2) is a severe, inherited eye disease caused by mutations in
the CNGA3 gene encoding the α subunit of the cone photoreceptor cyclic nucleotide-gated …

[HTML][HTML] Intraobserver repeatability and interobserver reproducibility of foveal cone density measurements in CNGA3-and CNGB3-associated achromatopsia

M Georgiou, KM Litts, N Singh, T Kane… - … Vision Science & …, 2020 - arvojournals.org
Purpose: To examine repeatability and reproducibility of foveal cone density measurements
in patients with CNGA3-and CNGB3-associated achromatopsia (ACHM) using split …

[HTML][HTML] Development of a chromatic pupillography protocol for the first gene therapy trial in patients with CNGA3-linked achromatopsia

J Lisowska, L Lisowski, C Kelbsch… - … & Visual Science, 2017 - jov.arvojournals.org
Purpose: To establish a feasible and sensitive pupillographic protocol to assess outer and
inner retinal function for the first gene therapy trial in achromatopsia patients (ACHM) with …

Retinal structure and function in achromatopsia: implications for gene therapy

V Sundaram, C Wilde, J Aboshiha, J Cowing, C Han… - Ophthalmology, 2014 - Elsevier
Purpose To characterize retinal structure and function in achromatopsia (ACHM) in
preparation for clinical trials of gene therapy. Design Cross-sectional study. Participants …

Vitreal delivery of AAV vectored Cnga3 restores cone function in CNGA3−/−/Nrl−/− mice, an all-cone model of CNGA3 achromatopsia

W Du, Y Tao, WT Deng, P Zhu, J Li, X Dai… - Human molecular …, 2015 - academic.oup.com
Abstract The CNGA3−/−/Nrl−/− mouse is a cone-dominant model with Cnga3 channel
deficiency, which partially mimics the all cone foveal structure of human achromatopsia 2 …

Cone-specific promoters for gene therapy of achromatopsia and other retinal diseases

GJ Ye, E Budzynski, P Sonnentag, TM Nork… - Human gene …, 2016 - liebertpub.com
Adeno-associated viral (AAV) vectors containing cone-specific promoters have rescued
cone photoreceptor function in mouse and dog models of achromatopsia, but cone-specific …

Retinal morphology of patients with achromatopsia during early childhood: implications for gene therapy

P Yang, KV Michaels, RJ Courtney, Y Wen… - JAMA …, 2014 - jamanetwork.com
Importance While older children and adults with achromatopsia have been studied, less is
known of young children with achromatopsia. Objectives To characterize the macular and …

Achromatopsia as a potential candidate for gene therapy

JJ Pang, J Alexander, B Lei, W Deng, K Zhang… - Retinal Degenerative …, 2010 - Springer
Achromatopsia is an autosomal recessive retinal disease involving loss of cone function that
afflicts approximately 1 in 30,000 individuals. Patients with achromatopsia usually have …

Gene Therapy Restores Missing Cone-Mediated Vision in the CNGA3−/− Mouse Model of Achromatopsia

S Michalakis, R Mühlfriedel, N Tanimoto… - Retinal Degenerative …, 2012 - Springer
The absence of cyclic nucleotide-gated (CNG) channels in cone photoreceptor outer
segments leads to achromatopsia, a severely disabling disease associated with the …